Clinical Trial Update: A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder [Phase 4]

View source ↗

Summary

A Phase 4 open-label trial evaluating the efficacy of vortioxetine in subjects with panic disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panic Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Siyan Clinical Corporation | Conditions: Panic Disorder | Phase 4 | Status: COMPLETED